Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diagnosis Related Group

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    3,028 result(s) found for: Diagnosis Related Group. Displaying page 1 of 152.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-002977-23 Sponsor Protocol Number: Tav02-13 Start Date*: 2013-12-13
    Sponsor Name:Montavit Ges.m.b.H.
    Full Title: Double-blind, randomised, placebo-controlled study evaluating the efficacy and Safety of Tavipec® capsules in acute Rhinosinusitis A prospective, multi-centre, parallel group, interventional clinic...
    Medical condition: Acute Rhinosinusitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-004106-25 Sponsor Protocol Number: EOP 1011E Start Date*: 2005-03-31
    Sponsor Name:(OSI) Eyetech, Inc
    Full Title: A Phase II randomised, dose-ranging, double-masked, multi-center trial, in parallel groups, to determine the safety, efficacy and pharmacokinetics of intravitreous injections of pegaptanib sodium c...
    Medical condition: Exudative Age Related Macular Degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    8 10025411 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002980-25 Sponsor Protocol Number: PRESERV Start Date*: 2020-06-12
    Sponsor Name:OSP.DEGLI INFERMI DI BIELLA
    Full Title: Randomized, multicenter, open-label study on PREvention of respiratory SEquelae of RSV bronchiolitis in preterm babies (PRESERV)
    Medical condition: Respiratory sincizial virus (RSV) bronchiolitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10038718 Respiratory syncytial virus bronchiolitis PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003121-94 Sponsor Protocol Number: P-Monofer-IBD-02 Start Date*: 2011-12-14
    Sponsor Name:Pharmacosmos A/S
    Full Title: A Prospective, Non-controlled, Safety Study of Intravenous Iron Isomaltoside 1000 (Monofer®) administered by a High Dosing Regimen in Subjects with Inflammatory Bowel Disease (PROMISE)
    Medical condition: Inflammatory Bowel Disease (IBD)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10002062 Anaemia iron deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-003206-58 Sponsor Protocol Number: CNTO1959PSO3013 Start Date*: 2019-06-29
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3b, Multicenter, Interventional, Randomized, Placebo controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
    Medical condition: Palmoplantar non-Pustular Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-005500-18 Sponsor Protocol Number: VITCLEAR Start Date*: 2013-11-18
    Sponsor Name:King's College Hospital NHS Foundation Trust [...]
    1. King's College Hospital NHS Foundation Trust
    2. King's College London
    Full Title: A pharmacokinetic study: ranibizumab, aflibercept and the effect of vitrectomy
    Medical condition: Age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    17.0 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000094-91 Sponsor Protocol Number: RC31/20/0518 Start Date*: Information not available in EudraCT
    Sponsor Name:Toulouse University Hospital
    Full Title: EFFECT OF INTRANASAL OXYTOCIN ON DYSPHAGIA RELATED TO OROPHARYNGO-OESOPHAGEAL DYSMOTILITY TRANSIT IN CHILDREN AND ADOLESCENTS WITH PRADER-WILLI SYNDROME: A PHASE 3 STUDY (DYSMOT)
    Medical condition: Prader-Willi Syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002485-12 Sponsor Protocol Number: RP1706 Start Date*: 2020-07-14
    Sponsor Name:Alimentiv Inc. (formerly Robarts Clinical Trials)
    Full Title: VERDICT: In actiVE ulcerative colitis, a RanDomIzed Controlled Trial for determination of the optimal treatment target
    Medical condition: Ulcerative Colitis (UC)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Ongoing) NL (Ongoing) PL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003042-15 Sponsor Protocol Number: ACU301 Start Date*: 2007-10-12
    Sponsor Name:Opko Health, Incorporated
    Full Title: A Phase 3, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis® c...
    Medical condition: Patients with subfoveal choroidal neovascularization associated with Age-Related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064930 Age-related macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) ES (Completed) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002213-60 Sponsor Protocol Number: GX1001 Start Date*: 2019-01-08
    Sponsor Name:Solid Biosciences Inc.
    Full Title: A randomized, controlled, open-label, single-ascending dose, phase I/II study to investigate the safety and tolerability, and efficacy of intravenous SGT-001 in male adolescents and children with D...
    Medical condition: Duchenne muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10052655 Duchenne muscular dystrophy gene carrier PT
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-004780-71 Sponsor Protocol Number: PROFERTIL Start Date*: Information not available in EudraCT
    Sponsor Name:Karolinska University Hospital
    Full Title: A phase III Randomized Double-Blinded Placebo-Controlled Study of Use of GnRHa during Chemotherapy for Fertility Protection of Young Women and Teenagers with Cancer - ProFertil
    Medical condition: Breast Cancer Acute Leukemia Lymphomas (Hodgkin and non-Hodgkin) Sarcomas (Osteo, Soft tissue and Ewing)
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001367-24 Sponsor Protocol Number: 217043 Start Date*: 2021-11-16
    Sponsor Name:GlaxoSmithKline SA
    Full Title: A Phase II, randomized, partially blinded study to assess the safety, tolerability and immunogenicity of meningococcal combined ABCWY vaccine when administered to healthy infants.
    Medical condition: Healthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10027249 Meningitis meningococcal PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) DE (Trial now transitioned) PL (Trial now transitioned) IT (Temporarily Halted) FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000719-15 Sponsor Protocol Number: CNTO1959PSO3001 Start Date*: 2014-10-24
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Seve...
    Medical condition: Moderate to Severe Plaque Type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2019-003204-12 Sponsor Protocol Number: ICI21/00025 Start Date*: 2022-03-16
    Sponsor Name:Consorcio PSMAR
    Full Title: Multicentre, randomised, double-blind, parallel-group, Phase III study to evaluate the genetic polymorphisms influence in the response to Ranibizumab and Bevacizumab treatment in patients with Age-...
    Medical condition: age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003699-36 Sponsor Protocol Number: 20050154 Start Date*: 2006-11-27
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2, Randomized, Double Blind, Placebo- Controlled Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Chemotherapy- Induced Thrombocytopenia in Su...
    Medical condition: Secondary prophylaxis for the treatment of chemotherapy induced thrombocytopenia (CIT) in subjects with Non-Small Cell Lung Cancer (NSCLC) receiving myelosuppressive chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10023780 Large cell lung cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) PT (Completed) AT (Prematurely Ended) HU (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-018741-65 Sponsor Protocol Number: OPH1001A Start Date*: 2010-04-21
    Sponsor Name:OPHTHOTECH CORPORATION
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-MASKED, CONTROLLED TRIAL TO ESTABLISH THE SAFETY AND EFFICACY OF INTRAVITREOUS INJECTIONS OF E10030 (ANTI-PDGF PEGYLATED APTAMER) GIVEN IN COMBINATION WITH LUCENTIS® I...
    Medical condition: Subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    14.1 10015919 - Eye disorders 10064930 Age-related macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) FR (Completed) BE (Completed) DE (Completed) ES (Completed) HU (Completed) IT (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003816-19 Sponsor Protocol Number: V4061 Start Date*: 2016-10-14
    Sponsor Name:ForSight VISION4, Inc
    Full Title: A Controlled Safety and Preliminary Efficacy Study of the V406 Port Delivery System in the Treatment of Choroidal Neovascularization Due toAge-Related Macular Degeneration
    Medical condition: Patients of either sex, 50 years of age or older, with a diagnosis of Choroidal Neovascularization CNV due to Age-Related Macular Degeneration AMD in the study eye
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001013-41 Sponsor Protocol Number: CIGE025A2210 Start Date*: 2008-01-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled study to demonstrate the efficacy of Xolair in an allergen bronchoprovocation study in two asthmatic populations defined by serum IgE concentrations
    Medical condition: Asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003018-42 Sponsor Protocol Number: OPH1004 Start Date*: 2014-10-10
    Sponsor Name:OPHTHOTECH CORPORATION
    Full Title: A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (Anti PDGF-B pegylated aptamer) administered in combination wi...
    Medical condition: Subfoveal neovascular age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    20.1 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Prematurely Ended) ES (Prematurely Ended) FI (Completed) NO (Completed) DE (Prematurely Ended) EE (Prematurely Ended) LV (Prematurely Ended) SK (Prematurely Ended) IT (Completed) AT (Prematurely Ended) HU (Completed) HR (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005501-27 Sponsor Protocol Number: 80843 Start Date*: 2022-02-04
    Sponsor Name:Rigshospitalet
    Full Title: 64Cu-DOTATATE PET/CT-skanning to diagnose macrophage infiltation in the heart valves of patients with infectiv endocarditis.
    Medical condition: Infective endocarditis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10014688 Endocarditis, valve unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 02:21:01 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA